NR 293 RUA Medication Teaching Plan Solved

NR 293 RUA Medication Teaching Plan Solved

Medication Teaching Plan

Ocrelizumab, under the trade name OCREVUS, was approved by the FDA in 2017, and the European Commission in 2018 for the treatment of multiple sclerosis (MS) Primary progressive MS, in adults (Asher, 2018). The drug has been on the market for only 3 years. As such, it is necessary to develop a brochure to inform, publicize, and identify the new pharmacological agent. Most importantly, before developing the brochure, it very important to understand the target audience to which the message will be aiming.

The target audience in this case will consider several variables such as age group, gender, social status, and education

level among others. Given that the main indications for Oocrelizumab are the management of MS, then the brochure will focus on reaching individuals who are at high risk of this condition (Ornia, 2016). Such individuals include young adults between the age of 20 to 50 years, women (Three times as likely to get MS as men), people from the north European descent, and those who have a high smoking habit among others.

The main reason behind the development of the brochure, as mentioned earlier, will be to inform, publicize, and identify. The brochure will inform the public on all the necessary information regarding the new drug, such as its indications, mode of action, dosage, mode of administration, interactions, and side effects among others (Way, Blazsin, Löfstedt, & Bouder, 2017). It is also intended to make the drug known to the public, for its effectiveness in the management of MS. Lastly, the brochure is intended to promote the identity of the company which produced the drug.